C4 Therapeutics Inc. has released a corporate presentation detailing advancements in their portfolio of degrader medicines aimed at transforming patient lives through targeted protein degradation. The presentation highlights the company's work in designing orally bioavailable degraders, with a focus on multiple myeloma and collaborations with leading global pharmaceutical companies. It also discusses the decision not to advance CFT1946 beyond Phase 1 trials and plans to seek partnerships for the BRAF program. Additionally, there is a mention of a license and collaboration agreement with Betta Pharmaceuticals for activities in Greater China. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。